Cargando…

Prognostic Value for Incidental Antihypertensive Therapy With β-Blockers in Metastatic Colorectal Cancer

Previous studies suggested that the incidental use of β-blockers might influence clinical outcome in solid tumors. We assessed the correlation between the incidental use of β-blockers and clinical outcome in colorectal cancer patients treated with first-line chemotherapy alone or in combination with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giampieri, Riccardo, Scartozzi, Mario, Del Prete, Michela, Faloppi, Luca, Bianconi, Maristella, Ridolfi, Francesca, Cascinu, Stefano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2015
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4616528/ https://www.ncbi.nlm.nih.gov/pubmed/26091452 http://dx.doi.org/10.1097/MD.0000000000000719

Ejemplares similares

Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysis
por: Bittoni, Alessandro, et al.
Publicado: (2015)

The role of Micro-RNAs in Hepatocellular Carcinoma: From Molecular Biology to Treatment
por: D’Anzeo, Marco, et al.
Publicado: (2014)

Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New
por: Faloppi, Luca, et al.
Publicado: (2016)

Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab
por: Giampieri, Riccardo, et al.
Publicado: (2015)

Clinical Evidence for Three Distinct Gastric Cancer Subtypes: Time for a New Approach
por: Bittoni, Alessandro, et al.
Publicado: (2013)

Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management
por: Del Prete, Michela, et al.
Publicado: (2015)

The Role of LDH Serum Levels in Predicting Global Outcome in HCC Patients Undergoing TACE: Implications for Clinical Management
por: Scartozzi, Mario, et al.
Publicado: (2012)

Role of Vascular Endothelial Growth Factor (VEGF) and VEGF-R Genotyping in Guiding the Metastatic Process in pT4a Resected Gastric Cancer Patients
por: Scartozzi, Mario, et al.
Publicado: (2012)

Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab
por: Scartozzi, Mario, et al.
Publicado: (2012)

Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma
por: Bianconi, Maristella, et al.
Publicado: (2016)

Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients
por: Scartozzi, M, et al.
Publicado: (2012)

Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients
por: Giampieri, Riccardo, et al.
Publicado: (2016)

Cancer Stem Cell Gene Profile as Predictor of Relapse in High Risk Stage II and Stage III, Radically Resected Colon Cancer Patients
por: Giampieri, Riccardo, et al.
Publicado: (2013)

The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management
por: Faloppi, Luca, et al.
Publicado: (2014)

The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy
por: Faloppi, Luca, et al.
Publicado: (2016)

Prognostic impact of mismatch repair genes germline defects in colorectal cancer patients: are all mutations equal?
por: Maccaroni, Elena, et al.
Publicado: (2015)

The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib
por: Faloppi, Luca, et al.
Publicado: (2015)

Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncology
por: Aprile, Giuseppe, et al.
Publicado: (2015)

VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib
por: Scartozzi, M, et al.
Publicado: (2013)

Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis
por: Giampieri, Riccardo, et al.
Publicado: (2017)

Prognostic and predictive value of KRAS mutation number in metastatic colorectal cancer
por: Ucar, Gokhan, et al.
Publicado: (2020)

Renin-Angiotensin System Blockers May Prolong Survival of Metastatic Non-Small Cell Lung Cancer Patients Receiving Erlotinib
por: Aydiner, Adnan, et al.
Publicado: (2015)

Apatinib as an optional treatment in metastatic colorectal cancer
por: Li, Aiyi, et al.
Publicado: (2019)

Are All Anti-Angiogenic Drugs the Same in the Treatment of Second-Line Metastatic Colorectal Cancer? Expert Opinion on Clinical Practice
por: Lai, Eleonora, et al.
Publicado: (2021)

Prognostic value of C-reactive protein to albumin ratio in metastatic colorectal cancer: A systematic review and meta-analysis
por: Pan, Yan, et al.
Publicado: (2021)

Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients
por: Scartozzi, M, et al.
Publicado: (2011)

Platelet to lymphocyte ratio is associated with tumor localization and outcomes in metastatic colorectal cancer
por: Acikgoz, Ozgur, et al.
Publicado: (2021)

Synchronous Resectable Metastatic Colorectal Cancer: Lymph Node Involvement Predicts Poor Outcome
por: Fu, Jianfei, et al.
Publicado: (2015)

The cardiotoxicity of cetuximab as single therapy in Chinese chemotherapy-refractory metastatic colorectal cancer patients
por: Tang, Xue-Miao, et al.
Publicado: (2017)

Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter
por: Bianconi, Maristella, et al.
Publicado: (2019)

Combined Analysis of EGFR and PTEN Status in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
por: Chen, Yu, et al.
Publicado: (2015)

Efficacy and safety of bevacizumab-based maintenance therapy in metastatic colorectal cancer: A meta-analysis
por: Ma, Hongbo, et al.
Publicado: (2019)

The efficacy and safety of irinotecan ± bevacizumab compared with oxaliplatin ± bevacizumab for metastatic colorectal cancer: A meta-analysis
por: Dai, Jiali, et al.
Publicado: (2019)

Metronomic capecitabine as maintenance treatment after first line induction with XELOX for metastatic colorectal cancer patients
por: Geng, Rui, et al.
Publicado: (2020)

Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer
por: Berardi, Rossana, et al.
Publicado: (2010)

The efficacy and safety of panitumumab plus irrinotecan-based chemotherapy in the treatment of metastatic colorectal cancer: A meta-analysis
por: Chen, Qiang, et al.
Publicado: (2016)

Regorafenib-induced retinal and gastrointestinal hemorrhage in a metastatic colorectal cancer patient with liver dysfunction: A case report
por: Tsuchihashi, Kenji, et al.
Publicado: (2017)

Efficacy and safety of metronomic chemotherapy in maintenance therapy for metastatic colorectal cancer: A systematic review of randomized controlled trials
por: Chen, Li, et al.
Publicado: (2022)

Risk of antiangiogenic adverse events in metastatic colorectal cancer patients receiving aflibercept in combination with chemotherapy: A meta-analysis
por: Ge, Pu, et al.
Publicado: (2023)

Trifluridine/tipiracil in combination with local therapy may be a favorable option for refractory metastatic colorectal cancer patients: A case report
por: Lin, Yu-Lin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_g8fni488ge9judh3vk904ka5kn